Glycogen synthase kinase 3β inhibitors induce apoptosis in ovarian cancer cells and inhibit in-vivo tumor growth
about
Clinicopathological and biological significance of aberrant activation of glycogen synthase kinase-3 in ovarian cancerCombination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models.Glycogen synthase kinase 3 protein kinase activity is frequently elevated in human non-small cell lung carcinoma and supports tumour cell proliferation.Spontaneous Transformation of Murine Oviductal Epithelial Cells: A Model System to Investigate the Onset of Fallopian-Derived Tumors.Novel MicroRNA Reporter Uncovers Repression of Let-7 by GSK-3βInhibition of GSK-3 induces differentiation and impaired glucose metabolism in renal cancer.MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.GSK-3 inhibition overcomes chemoresistance in human breast cancer.Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer.Clinical significance and biological role of Wnt10a in ovarian cancer.Inhibition of Glycogen Synthase Kinase 3β Blocks Mesomesenchymal Transition and Attenuates Streptococcus pneumonia-Mediated Pleural Injury in Mice.In vitro and in vivo anti-tumor and anti-inflammatory capabilities of the novel GSK3 and CKD9 inhibitor ABC1183.9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma.Aberrant expression of glycogen synthase kinase-3β in human breast and head and neck cancer
P2860
Q33831250-A70613EB-877F-4603-9DB1-9DDC76CA187EQ33869702-D764D325-66D2-4496-B41D-1BB6A1A59514Q34654039-304D5805-BD86-46F1-998D-F64DE0AE95B2Q35859678-9294D79B-E7E9-4B23-B54D-3894209BAC30Q36958666-3552C6A8-4D56-418C-BC37-FCE68E10E640Q37640802-8D57CEE1-D0F4-4849-80D5-A21A7DAFA1A9Q37694818-2F13C0B1-BD7B-43C0-8507-704FCACA78E0Q38757733-1EE98084-14DB-4829-9CAC-0942E5A3D6BFQ39067484-379E24D6-87C6-41EB-B8B3-030F2B4BBCE6Q47134956-30B65855-D173-4C51-8C51-81AF2FD3A9A0Q47599408-DA0FC049-F4C6-41FB-9B46-E4440066F74DQ50056226-17D166DF-FFCC-43D4-8DAC-B6915AAF4FF5Q54977695-6E2C34AC-7E68-424C-ADBC-1E8720C9226DQ58572626-8B77BFAF-C085-4896-B5AA-F4242BD09558
P2860
Glycogen synthase kinase 3β inhibitors induce apoptosis in ovarian cancer cells and inhibit in-vivo tumor growth
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Glycogen synthase kinase 3β in ...... d inhibit in-vivo tumor growth
@ast
Glycogen synthase kinase 3β in ...... d inhibit in-vivo tumor growth
@en
type
label
Glycogen synthase kinase 3β in ...... d inhibit in-vivo tumor growth
@ast
Glycogen synthase kinase 3β in ...... d inhibit in-vivo tumor growth
@en
prefLabel
Glycogen synthase kinase 3β in ...... d inhibit in-vivo tumor growth
@ast
Glycogen synthase kinase 3β in ...... d inhibit in-vivo tumor growth
@en
P2093
P2860
P1433
P1476
Glycogen synthase kinase 3β in ...... d inhibit in-vivo tumor growth
@en
P2093
Amanda G Muehlbauer
Arsen M Gaisin
Franck Gallier
Joanna E Burdette
Tyvette S Hilliard
P2860
P304
P356
10.1097/CAD.0B013E32834AC8FC
P577
2011-11-01T00:00:00Z